Monoclonal Antibodies: Scientific Classification and Pharmacovigilance Landscape

Purpose and Scope

Monoclonal antibodies form one of the most diverse families of biological medicinal products. They share an antibody-based molecular architecture, but products within the family can differ profoundly in target, epitope, mechanism of action, Fc-mediated activity, molecular format, pharmacokinetics, clinical indication and safety profile. A useful classification therefore cannot be reduced to a single hierarchy. The same antibody can be classified simultaneously by how it was engineered, what it targets, how it produces its therapeutic effect and what molecular format it uses.

This article provides the master scientific classification for the monoclonal-antibody branch of the QPPV.com biological-medicines library. Its purpose is to give the reader a landscape before individual antibody families and products are examined. The classification is deliberately multidimensional: it separates characteristics that describe the antibody itself from characteristics that describe its biological target and therapeutic function.

The distinction matters for pharmacovigilance. Antibody origin may inform the history and potential immunogenicity of a product, but target biology often provides a stronger basis for anticipating on-target effects. Molecular architecture may determine whether Fc-mediated effector functions are relevant, while indication and treatment context determine which consequences are clinically important. A scientifically useful pharmacovigilance classification therefore needs to preserve these relationships rather than assign every antibody to one mutually exclusive box.

The article focuses on therapeutic monoclonal antibodies and closely related antibody-derived formats where their inclusion helps explain the landscape. EMA defines monoclonal antibodies as immunoglobulins with defined specificity derived from a monoclonal cell line and recognises related products such as fragments, conjugates and fusion proteins as products whose applicability requires consideration of their specific properties. [1]

The Master Classification

The most useful way to understand monoclonal antibodies is to begin with five complementary questions:

1. How was the antibody derived and engineered?
2. What molecular architecture does it have?
3. What does it bind?
4. What biological effect does target engagement produce?
5. How is that biological effect used therapeutically?

These questions generate overlapping classifications rather than a single taxonomic tree. The following map is therefore the master landscape for the series.

MONOCLONAL ANTIBODIES
│
├── 1. ORIGIN AND ENGINEERING
│   ├── Murine
│   ├── Chimeric
│   ├── Humanised
│   └── Fully human
│
├── 2. MOLECULAR ARCHITECTURE
│   ├── Conventional monoclonal antibodies
│   ├── Fc-engineered antibodies
│   ├── Antibody fragments
│   ├── Bispecific / multispecific antibodies
│   ├── Antibody–drug conjugates
│   └── Other engineered antibody formats
│
├── 3. TARGET CLASS
│   ├── Soluble mediators / cytokines
│   ├── Cell-surface antigens
│   ├── Receptors and signalling pathways
│   ├── Immune checkpoints / immune regulators
│   ├── Enzymes and circulating proteins
│   ├── Complement components
│   ├── Growth factors / angiogenic pathways
│   └── Other molecular targets
│
├── 4. MECHANISM OF ACTION
│   ├── Ligand neutralisation
│   ├── Receptor blockade
│   ├── Receptor agonism / activation
│   ├── Cell depletion
│   ├── Immune modulation
│   ├── Targeted delivery of a payload
│   └── Other target-dependent effects
│
└── 5. THERAPEUTIC APPLICATION
    ├── Oncology
    ├── Immunology / inflammatory disease
    ├── Haematology
    ├── Neurology
    ├── Cardiovascular and metabolic disease
    ├── Infectious disease
    ├── Ophthalmology
    └── Other therapeutic areas

The diagram should not be read from top to bottom as though each antibody belongs to only one branch. Each numbered dimension describes the same product from a different scientific perspective. A fully human antibody may be an IgG1 receptor antagonist directed against a cytokine and used in inflammatory disease. Another fully human antibody may be an IgG4 antibody directed against a different receptor and used in oncology. Their shared origin category says little about whether they share a safety profile.

The converse is equally important. Two antibodies directed at the same target may differ in epitope, affinity, Fc activity, molecular format, dose, route and indication. They may therefore share a biological hypothesis without having identical clinical effects. Target and mechanism are powerful tools for forming safety hypotheses, but they are not substitutes for product-specific evidence.

Classification by Origin and Engineering

The historical classification of therapeutic monoclonal antibodies into murine, chimeric, humanised and fully human products describes the extent and arrangement of non-human and human immunoglobulin sequence. It remains useful because antibody engineering evolved through these stages and because sequence composition can influence the potential for an unwanted immune response. It should not, however, be interpreted as a quantitative ranking of clinical safety.

EMA's immunogenicity guideline for monoclonal antibodies emphasises evaluation of unwanted immune responses in the context of the particular antibody and clinical indication. Immunogenicity can be influenced by product quality, formulation, dose, route, treatment duration and patient or disease factors. [2]

The origin classification should therefore be treated as a descriptive engineering axis, not as the primary pharmacovigilance taxonomy. The clinically relevant question is whether the antibody's molecular characteristics and exposure create a plausible and observed immune response and whether that response has clinical consequences.

How to Use This Classification

The master map is an organising framework, not a legal taxonomy and not a prediction algorithm. Its purpose is to let the reader move from a broad antibody category to the particular scientific characteristics that matter for a safety question. The later articles in this branch will therefore use the map selectively: a bispecific antibody will be classified by its architecture and dual-target mechanism; an antibody–drug conjugate will require attention to both antibody targeting and payload toxicity; and a conventional monoclonal antibody will usually be understood primarily through its target, mechanism, Fc characteristics and clinical context.

This distinction between classification and evidence is fundamental. A product's classification identifies relevant questions. Pharmacovigilance evidence determines the answers.

Classification by Molecular Architecture

A second axis concerns the physical organisation of the antibody molecule. Conventional therapeutic monoclonal antibodies are commonly full-length immunoglobulins, frequently of the IgG class, but antibody engineering has produced formats with different valency, specificity, Fc behaviour, size and pharmacokinetic properties.

Conventional monoclonal antibodies

A conventional monoclonal antibody contains antigen-binding regions and, where the format includes an Fc region, a constant region capable of interacting with Fc receptors and complement. The therapeutic effect may depend primarily on target binding or may also require Fc-mediated effector function.

Fc-engineered antibodies

Engineering can alter Fc interactions to increase, reduce or otherwise modify effector functions and pharmacokinetic behaviour. Such changes can alter the intended mechanism or the biological consequences of target engagement. Fc characteristics should therefore be considered when interpreting safety findings involving immune-cell activation, depletion or antibody persistence.

Antibody fragments

Fragments retain selected antibody-binding functions without the complete structure of a conventional immunoglobulin. Their altered size, valency, tissue penetration, elimination and Fc activity can materially change their pharmacology. They are therefore related to monoclonal antibodies but should not automatically inherit the clinical characteristics of full-length antibodies.

Bispecific and multispecific antibodies

Bispecific or multispecific antibodies are engineered to recognise more than one molecular target or epitope. Their pharmacology can arise from simultaneous engagement of two biological systems, bringing together cells or modifying two signalling pathways. This creates safety questions that may not be represented adequately by considering either target in isolation.

Antibody–drug conjugates

Antibody–drug conjugates combine antibody-mediated target recognition with a linked pharmacologically active payload. Their safety profile therefore reflects at least two interacting components: target-directed exposure and payload-related toxicity. The antibody influences distribution and targeting, while the linker and payload influence intracellular release and toxicity.

EMA's monoclonal-antibody quality guideline states that its general principles may apply to related products such as fragments, conjugates and fusion proteins on a case-by-case basis according to their specific properties. [1]

Why Architecture Is a Pharmacovigilance Dimension

Molecular architecture influences pharmacokinetics, tissue distribution, target engagement, immune effector activity and immunogenicity. These effects can alter both the expected safety profile and the interpretation of unexpected events.

An antibody fragment lacking an Fc region cannot be assumed to produce the same Fc-mediated effects as a full-length IgG. A bispecific antibody can generate a pharmacological effect through simultaneous engagement of two targets. An antibody–drug conjugate can introduce toxicities associated with its payload that would not be predicted from the antibody component alone. These are mechanistic differences with consequences for risk assessment.

This architecture axis therefore provides the bridge from the master classification to later subtype articles. Bispecific antibodies, antibody–drug conjugates and selected engineered formats should be treated as distinct branches where their molecular design creates sufficiently different pharmacology or safety questions.

Classification by Target

The third major axis asks what the antibody recognises. Target classification is particularly useful because target biology often determines the principal on-target pharmacological consequences of treatment.

Major target groupings include soluble mediators, cell-surface antigens, receptors, immune-regulatory molecules, enzymes, complement components and growth-factor pathways. These categories are not exhaustive, and some targets can reasonably be described at more than one biological level.

The target classification is most informative when combined with mechanism. An antibody against a soluble cytokine may neutralise the ligand. An antibody against a receptor may block or activate signalling. An antibody against a cell-surface antigen may deplete the target-bearing cell through Fc-dependent mechanisms, block its function, deliver a payload or produce another effect. Therefore, the target name alone does not define the pharmacology.

Target classification should therefore be used to build mechanistic hypotheses, not to assume a class effect. The existence of a plausible biological mechanism is one component of evidence; observed clinical data determine whether a risk should be considered established, potential or unsupported.

Classification by Therapeutic Application

Therapeutic indication provides a clinically oriented axis. Monoclonal antibodies are used across oncology, immunology, inflammatory disease, haematology, neurology, ophthalmology, infectious disease and other fields. Indication is not a biological classification in the strict molecular sense, but it is essential for interpreting safety because disease state, concomitant therapy, dose and treatment duration can modify both baseline risk and the consequences of target modulation.

The same antibody may be authorised for multiple indications, and the safety profile may not be identical across those uses. A risk may be related to the mechanism and therefore relevant across indications, while its observed frequency or clinical significance may vary with population and exposure. Conversely, an event prominent in one therapeutic setting may be strongly influenced by the underlying disease or concomitant treatment.

Therapeutic area should therefore be considered a clinical context layer, not a substitute for molecular or mechanistic classification.

Classification by Mechanism of Action

The fourth scientific axis describes what happens after the antibody binds its target. The principal mechanisms can be organised into ligand neutralisation, receptor blockade, receptor activation, cell depletion, immune modulation and targeted delivery.

These mechanisms are not mutually exclusive. Target binding can block a receptor while Fc-mediated effector function contributes to depletion of cells expressing that receptor. In such cases, safety assessment should consider both mechanisms and determine which best explains the observed event.

Why Target and Mechanism Must Be Kept Together

A target label by itself is insufficient for pharmacovigilance. The same molecular target can be approached through different epitopes, binding modes or antibody formats, producing different degrees of receptor occupancy or different downstream consequences. Conversely, antibodies against different targets can converge on a common physiological pathway and produce related clinical outcomes.

Mechanistic classification therefore sits between molecular identity and clinical evidence. It provides a biologically coherent basis for asking whether an observed event could plausibly result from target modulation, but it does not establish that the event is caused by the antibody or shared by all antibodies in the same mechanistic category.

How the Classification Axes Intersect

The scientific value of the master map appears when the axes are combined. Consider a hypothetical antibody with the following characteristics:

The resulting safety hypotheses would be derived principally from target biology, depletion and Fc activity, while immunogenicity would be assessed independently. Changing the Fc characteristics could alter expected effector function without changing the target. Changing the target could radically alter safety despite retaining the same antibody architecture. Changing the indication could alter the clinical consequences without changing the molecule.

This illustrates why the classification cannot be represented accurately as a single linear hierarchy. Each product occupies a coordinate in a multidimensional scientific space.

From Classification to Pharmacovigilance

The purpose of the classification is ultimately practical. Pharmacovigilance requires a framework for deciding what information should be considered together and what information should remain product-specific. Classification helps define the starting hypothesis, but it should never predetermine the conclusion.

A shared target can support investigation of a potential class effect. Shared antibody architecture can identify common product characteristics. Shared mechanism can suggest biological plausibility. Shared therapeutic indication can identify common confounders. None of these relationships alone proves that two antibodies have the same safety profile.

Conversely, differences between antibodies should not automatically be interpreted as evidence of different safety. Evidence must establish whether the difference is clinically relevant. The classification therefore serves as a scientific organising framework for evidence, rather than a replacement for pharmacovigilance assessment.

Class-Level, Family-Level and Product-Level Knowledge

The hierarchy becomes useful when it is applied at three different levels of pharmacovigilance reasoning.

At the class level, the antibody architecture and broad biological properties establish general scientific context. This level can identify characteristics that recur across many antibodies, such as the potential relevance of immunogenicity or Fc-mediated functions.

At the family or mechanism level, shared target biology can support more specific safety hypotheses. An antibody family directed at the same pathway may have related pharmacological consequences, but the evidence still needs to establish whether a particular risk is shared and under what circumstances.

At the product level, the actual molecule, formulation, manufacturing history, dose, route, indication, exposure and patient population become decisive. Product-specific evidence should not be discarded merely because a broader class or family relationship exists.

This three-level approach prevents two common analytical errors. The first is over-pooling, in which biologically related products are treated as though their safety evidence were interchangeable. The second is excessive isolation, in which established biological knowledge about a mechanism is ignored because products are assessed separately. Good pharmacovigilance uses the level of aggregation that matches the scientific question.

The Classification and Product Identity

The classification also has implications for product identification. A report concerning a monoclonal antibody should identify the medicinal product actually administered rather than only the target, active substance class or broader therapeutic family. This is particularly important where multiple antibodies act on the same pathway or where a reference biological medicine and biosimilars coexist.

Product identity provides the anchor for subsequent comparative analysis. Once the product is known, the assessor can place it within the relevant antibody architecture, target and mechanism categories and can then ask whether evidence from related products is scientifically relevant. The order matters: classification should support interpretation of product-specific evidence, not replace it.

The Classification and Immunogenicity

Immunogenicity is another cross-cutting characteristic that does not map neatly onto one branch of the taxonomy. Antibody origin is relevant, but immunogenicity is influenced by multiple product-related, treatment-related and patient-related factors. EMA's guidance specifically notes that unwanted immune responses can have consequences such as altered pharmacokinetics, loss of efficacy, hypersensitivity and other clinically significant effects. [2]

Accordingly, "fully human", "humanised" or "chimeric" should not be used as shorthand for a particular pharmacovigilance conclusion. The actual product and clinical evidence remain necessary. The same principle applies when comparing conventional antibodies with engineered formats: altered architecture can change immunogenicity, but the direction and clinical significance must be demonstrated.

The Classification and Biological Manufacturing

Monoclonal antibodies are biological products whose characteristics depend on the manufacturing process as well as the intended molecular design. EMA's quality guideline addresses development, production, characterisation and control, including relevant structural and biological attributes. [1]

Manufacturing therefore forms an additional cross-cutting dimension of the landscape even though it is not represented as a branch in the master tree. A change in manufacturing process is not automatically a pharmacovigilance signal, but it can be relevant when a change in product characteristics could alter clinical behaviour. Comparability assessment, quality evidence and post-authorisation pharmacovigilance provide complementary parts of the lifecycle evidence.

A Practical Reading of the Master Map

For a pharmacovigilance professional encountering an unfamiliar monoclonal antibody, the map can be used as a sequence of questions:

1. What is the molecular format? Full-length antibody, fragment, bispecific, conjugate or another engineered form?
2. How has the antibody been engineered? Murine, chimeric, humanised, fully human or otherwise modified?
3. What is the target? Soluble mediator, receptor, cell-surface antigen, immune regulator or another target?
4. What does target engagement do? Neutralises, blocks, activates, depletes, modulates or delivers?
5. What is the clinical context? Disease, population, dose, route, duration and concomitant treatment?
6. What product-specific characteristics matter? Formulation, manufacturing history, immunogenicity and traceability?
7. Which related-product evidence is genuinely relevant? Class, mechanism, family, reference-product or product-specific evidence?

The resulting assessment moves from classification to evidence rather than from classification directly to a safety conclusion.

Boundaries of the Classification

Not every antibody-derived medicinal product belongs in exactly the same category. Some products combine antibody recognition with other biological or chemical components, while others use antibody fragments or multispecific architectures that differ materially from conventional monoclonal antibodies. EMA's guidance explicitly allows the principles for monoclonal antibodies and related products to be applied according to the properties of the specific product. [1]

The QPPV.com classification should therefore remain evidence-led and adaptable. A branch should be expanded into a dedicated article when its scientific architecture, regulatory context or pharmacovigilance characteristics justify the distinction. It should not be created solely because a different product name or technology exists.

The MAb Library That Follows

The master map establishes the navigation structure for the next level of the biological-medicine library. The next articles should therefore descend in a controlled sequence: first into major antibody architectures that create distinct pharmacology, then into important target or therapeutic families, and finally into individual products.

This produces a coherent progression:

MASTER MAb LANDSCAPE
        ↓
MOLECULAR / FUNCTIONAL SUBCLASS
        ↓
TARGET OR THERAPEUTIC FAMILY
        ↓
INDIVIDUAL MONOCLONAL ANTIBODY
        ↓
PRODUCT-SPECIFIC PHARMACOVIGILANCE

The classification is consequently not an endpoint. It is the scientific framework that allows every later article to answer the more specific question of where an antibody belongs and why that location matters for its safety profile.

References

1. European Medicines Agency. Guideline on development, production, characterisation and specification for monoclonal antibodies and related products – Revision 1. EMA/CHMP/BWP/532517/2008. Effective 1 September 2016. citeturn0search1turn0search36
2. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use. EMA/CHMP/BMWP/86289/2010. Current effective version. citeturn0search2turn0search37
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Product- or Population-Specific Considerations II: Biological medicinal products. EMA/168402/2014. citeturn0search35
4. European Medicines Agency. Biosimilar medicines: Overview. Information on biological medicinal products and the relationship between molecular complexity, biological-product characteristics and biosimilarity. citeturn0search0

Regulatory Note

This article provides a scientific classification and pharmacovigilance framework for understanding monoclonal antibodies. The dimensions used in the classification—origin, engineering, molecular architecture, target, mechanism and therapeutic application—are analytical categories and should not be assumed to constitute mutually exclusive legal regulatory classifications. EU regulatory requirements must be determined from applicable legislation, current EMA guidance and product-specific regulatory documentation.

The EMA monoclonal-antibody quality guideline currently identifies Revision 1 as the effective version and notes that the guideline is under revision. The immunogenicity guideline for monoclonal antibodies remains the current effective guideline identified by EMA. Regulatory status should therefore be checked against the current EMA source before applying a requirement to a particular product or development programme. citeturn0search1turn0search2

The pharmacovigilance framework remains the applicable general EU GVP framework, with biological-product-specific considerations where relevant. Classification in this article is intended to improve scientific reasoning and navigation of the QPPV.com biological-medicines library; it does not create additional regulatory obligations. citeturn0search35